Harish Gopalakrishna

Dr. Harish Gopalakrishna


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2024 in Hepatology Communications
Verified
Journal Article
Closed access
MMMaria Mironova
Maria Mironova
HGHarish Gopalakrishna
Harish Gopalakrishna
GFGian Rodriguez Franco
Gian Rodriguez Franco
SHSteven M. Holland
Steven M. Holland
CKChristopher Koh
Christopher Koh
THTheo Heller
Theo Heller
A granuloma is a discrete collection of activated macrophages and other inflammatory cells. Hepatic granulomas can be a manifestation of localized liver disease or be a part of a systemic process, usually infectious or autoimmune. A liver biopsy is required for the detection and evaluation of granulomatous liver diseases. The prevalence of granulomas on liver biopsy varies from 1% to 15%. They may be an incidental finding in an asymptomatic individual, or they may represent granulomatous hepatitis with potential to progress to liver failure, or in chronic disease, to cirrhosis. This review focuses on pathogenesis, histological features of granulomatous liver diseases, and most common etiologies, knowledge that is essential for timely diagnosis and intervention.

1 February 2024 in Current Hepatology Reports
Verified
Journal Article
Open access
PDF file
HGHarish Gopalakrishna
Harish Gopalakrishna
MMMaria Mironova
Maria Mironova
HDHarel Dahari
Harel Dahari
CKChristopher Koh
Christopher Koh
THTheo Heller
Theo Heller
Purpose of Review: Hepatitis D Virus (HDV), although a small defective virus, poses a substantial public health challenge due to lack of awareness, underrecognized prevalence, and limited treatment options. Universal HDV screening within hepatitis B virus (HBV) cohorts is essential to address this issue. Despite its aggressive nature, effective HDV therapies have remained elusive for over four decades. Recent Findings: Advances in understanding HDV’s biology and clinical behavior offer potential therapeutic breakthroughs, fostering optimism. As insights grow, effective and targeted therapies are being developed to improve HDV management. Summary: This review delves into HDV’s intricate structure and biology, highlighting formidable hurdles in antiviral development. It emphasizes the importance of widespread screening, exploring noninvasive diagnostics, and examining current and emerging innovative therapeutic strategies. Moreover, the review explores models for monitoring treatment response. In essence, this review simplifies the complexities of effectively combating HDV.

10 February 2024 in Current Hepatology Reports
Verified
Journal Article
Open access
PDF file
HGHarish Gopalakrishna
Harish Gopalakrishna
MGMarc G. Ghany
Marc G. Ghany
Purpose of Review: Advancements in our understanding of the hepatitis B viral (HBV) life cycle have paved the way for novel approaches to treat HBV infection. This review summarizes the various strategies being pursued to achieve a functional cure, defined as loss of hepatitis B surface antigen (HBsAg) and absence of viral replication 6 months off-therapy. Recent Findings: Direct acting antiviral, host targeting antiviral, and immunological approaches are in various stages of development as treatment for chronic HBV infection. Summary: Novel treatments are being developed in pursuit of a cure for HBV. Current evidence suggests a single therapeutic agent alone may be insufficient, necessitating the need for combination therapy targeting HBV and the host immune response. Ongoing research focused on identifying the best therapeutic combination holds promise in achieving functional cure for HBV.

9 December 2024 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
HGHarish Gopalakrishna
Harish Gopalakrishna
MGMarwan Ghabril
Marwan Ghabril
JGJiezhun Gu
Jiezhun Gu
YLYi Ju Li
Yi Ju Li
RFRobert J. Fontana
Robert J. Fontana
FNFor The Drug-Induced Liver Injury Network
For The Drug-Induced Liver Injury Network
Objectives: Concerns about drug-induced liver injury (DILI) may deter physicians from prescribing medications for alcohol use disorder (MAUD). We aim to explore DILI due to MAUD in Drug-Induced Liver Injury Network (DILIN) prospective study. Methods: High-confidence DILI cases (ie, definite, highly likely, or probable) due to MAUD in DILIN prospective study (2004–2024) were included. Demographic, clinical, laboratory data, and 6-month outcomes were analyzed. HLA allele frequency (AF) of disulfiram cases was compared to matched controls with DILI due to non-MAUD (DILI controls). Results: Among 1975 high-confidence cases, 13 were attributed to MAUD (11 disulfiram; 1 naltrexone and 1 baclofen; and none from acamprosate). Median age was 45 years, with 77% female and 85% White. All had hepatocellular injury. In disulfiram group, the median time for DILI occurrence was 34 days. Eight patients developed jaundice, with 3 fatal or near-fatal cases (2 liver transplantation and 1 liver-related death). Five (71%) patients with severe or fatal disulfiram DILI had underlying liver disease. AF for HLA-C*01:02 (OR, 6.29; P = 0.02) and DRB1*09:01 (OR, 10.16; P = 0.02) were significantly higher in disulfiram cases than in DILI controls. DILI from baclofen and naltrexone was mild and self-limited with no chronic DILI. Conclusions: Disulfiram is the leading cause of DILI among MAUD and is most common in women. Disulfiram can cause severe DILI and is associated with HLA-C*01:02 and DRB1*09:01. Baclofen and naltrexone can cause mild to moderate self-limited DILI. There were no cases of acamprosate. These findings suggest DILI due to MAUD are less frequent.

4 April 2025 in Hepatology
Verified
Journal Article
Closed access
MMMaria Mironova
Maria Mironova
HGHarish Gopalakrishna
Harish Gopalakrishna
CKChristopher Koh
Christopher Koh
DKDavid E. Kleiner
David E. Kleiner
THTheo Heller
Theo Heller
The term porto-sinusoidal vascular disease (PSVD) was introduced in 2019 to describe a group of liver conditions that can lead to portal hypertension (PH) in the absence of cirrhosis or portal vein thrombosis, with or without specific findings on liver histology. The new nomenclature has facilitated the consolidation of knowledge on diseases previously referred to by various terms, including Banti’s disease, non-cirrhotic portal hypertension, non-cirrhotic portal fibrosis, and idiopathic portal hypertension, while excluding certain etiologies like sarcoidosis, congenital hepatic fibrosis, and Budd-Chiari syndrome. The prevalence and recognition of the disorder has been increasing. Advances in diagnostics and treatment have improved life expectancy for patients with associated conditions, such as immunodeficiencies and autoimmune diseases. Similar to cirrhosis, patients with PSVD may experience complications of PH, including variceal bleeding and ascites. However, less is known about its natural history, screening strategies, prognosis, and treatment options. This review discusses methods for assessing PSVD, including clinical and histological features, imaging techniques, and currently available treatments. It also addresses the challenges posed by the new nomenclature and the remaining questions in disease assessment. Export

17 April 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MMMaria Mironova
Maria Mironova
HGHarish Gopalakrishna
Harish Gopalakrishna
GRGracia Maria Viana Rodriguez
Gracia Maria Viana Rodriguez
NMNehna Abdul Majeed
Nehna Abdul Majeed
AHAsif A. Hitawala
Asif A. Hitawala
THTheo Heller
Theo Heller